Characterization of a Novel Aldose Reductase Inhibitor, TAT, and Its Effects on Streptozotocin-Induced Diabetic Neuropathy in Ra

The Japanese Journal of Pharmacology

Volumn 61, Issue 3, 1993, Pages 221-227

  Inukai, Shinji ^a   Agata, Mitsuji ^a   Sato, Manami ^a   Naitou, Akira ^a  

^a Wakamoto Pharmaceutical Co Ltd   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetic neuropathy; Epalrestat, Sorbitol; Motor nerve conduction velocity

Indexed keywords

[5 (3 THIENYL)TETRAZOL 1 YL]ACETIC ACID; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; GLUCOSE; PONALRESTAT; SORBITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETIC NEUROPATHY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; LENS; LIVER; MALE; MOTOR NERVE CONDUCTION; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RABBIT; RAT; SCIATIC NERVE;

ALDEHYDE REDUCTASE; ANIMAL; DIABETIC NEUROPATHIES; HUMAN; IN VITRO; MALE; MICE; MICE, INBRED C57BL; NEURAL CONDUCTION; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; SORBITOL; SUGAR ALCOHOLS; TETRAZOLES; THIOPHENES;

EID: 0027229933     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.61.221     Document Type: Article

References (16)

1. Formation of polyols by the lens of the rat with sugar cataract. Nature 184, 194-195 (1959)
2. Varma, S.D., Schocket, S.S. and Richards, R.D.: Implications of aldose reductase in cataracts in human diabetes. Invest. Ophthalmol. Vis. Sci. 18, 237-241 (1979)
3. Akagi, Y., Kador, P.F., Kuwabara, T. and Kinoshita, J.H.: Aldose reductase localization in human retinal mural cells. Invest. Ophthalmol. Vis. Sci. 24, 1516-1519 (1983)
4. Gabby, K.H.: The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 288, 831-836 (1973)
5. Cohen, M.P.: Aldose reductase, glomerular metabolism and diabetic neuropathy. Metabolism 35, 55-59 (1986)
6. Yue, D.K., Hanwell, M.A., Satchell, P.M. and Turtle, J.R.: The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 31, 789-794 (1982)
7. Simard-Duquesne, N., Greselin, E., Dubuc, J. and Dvornik, D.: The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism 34, 885-892 (1985)
8. Terashima, H., Hama, K., Yamamoto, R., Tsuboshima, M., Kikkawa, R., Hatanaka, I. and Shigeta, Y.: Effect of a new aldose reductase inhibitor on various tissues. J. Pharmacol. Exp. Ther. 229, 226-230 (1984)
9. Griffin, B.W., McNatt, L.G., Chandler, M.L. and York, B.M.; Effect of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats. Metabolism 36, 486-490 (1987)
10. Stribling, D., Mirrlees, D.J., Harrison, H.E. and Earl, D.C.N.: Properties of ICI 128,436. a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism 34, 336-344 (1985)
11. Ao, S., Shingu, Y., Kikuchi, C., Takano, Y., Nomura, K., Fujiwara, T., Ohkubo, Y., Notsu, Y. and Yamaguchi, I.: Characterization of a novel aldose reductase, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism 40, 77-87 (1991)
12. Tawada, H., Sugiyama, Y., Ikeda, H., Yamamoto, Y. and Meguro, K.: Studies on antidiabetic agent I.V. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives. Synthesis and biological activity. Chem. Pharm. Bull. (Tokyo) 38, 1238-1245 (1990)
13. Mylari, B.L., Larson, E.R., Beyer, T.A. and Zembroaski, W.J.: Novel, potent aldose reductase inhibitors, 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methy-1-phthalaz-ine-acetic acid (Zopolrestat) and congeners. J. Med. Chem. 34, 108-122 (1991)
14. Maragoudakis, M.E., Wasvary, J., Hankin, H. and Gargiulo, P.: Human placenta aldose reductase. Forms sensitive and insensitive to inhibition by alrestatin. Mol. Pharmacol. 25, 425-430 (1984)
15. Miyoshi, T. and Goto, I.: Serial in vivo determinations of nerve conduction velocity in rat tail. Physiological and pathological changes. Electroenceph. Clin. Neurophysiol. 35, 125-131 (1973)
16. Kikkawa, R., Hatanaka, I., Yasuda, H., Kobayashi, N., Shigeta, Y., Terashima, H., Morimura, T. and Tsuboshima, M.: Effects of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E-methyl-3-phenylpropenylidene] rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-dia-betic rats. Diabetologia 24, 290-292 (1983)